Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, International, Open-label, Safety Study of ND0612, a Solution of Levodopa/Carbidopa Delivered Via a Pump System as a Continuous Subcutaneous Infusion in Subjects With Advanced Parkinson's Disease

Next Previous
Trial Profile

A Multicenter, International, Open-label, Safety Study of ND0612, a Solution of Levodopa/Carbidopa Delivered Via a Pump System as a Continuous Subcutaneous Infusion in Subjects With Advanced Parkinson's Disease

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Apr 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Levodopa/carbidopa (Primary) ; Levodopa
  • Indications Parkinson's disease
  • Focus Adverse reactions
  • Acronyms BeyoND
  • Sponsors NeuroDerm

    • Most Recent Events

    • 12 Apr 2024 According to a Mitsubishi Tanabe Pharma Corporation Media Release, data from the study will be presented at the American Academy of Neurology (AAN) 2024 Annual Meeting being held in Denver, Colo., Apr.13-18, 2024.
    • 14 Mar 2024 According to a NeuroDerm media release, analyses of results from the ongoing BouNDless trial complement the long-term safety data from the BeyoND study (NCT02726386) including patients in their eighth year of follow-up.
    • 05 Mar 2024 According to a Mitsubishi Tanabe Pharma America Media release, the company will present a posters in Parkinson's disease (PD) will be shared at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2024), being held in Lisbon, Portugal, and virtually, from March 5-9
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top